In addition, the cells express wild-type (MCF-7) or different mutated forms (T47D, MDA-MB-468, and MDA-MB-231) of the tumor-suppressor protein p53 which was shown to enhance the activity of the mevalonate pathway when mutated in breast cancer10,45,46. This evidence concerns the gene TP53 and medical procedure.